Biological drugs targeting the immune response in the therapy of psoriasis

Saveria Pastore1, Emanuela Gubinelli2, Luca Leoni2, Desanka Raskovic2, Liudmila Korkina11Laboratory of Tissue Engineering and Cutaneous Physiopathology; 2Second Dermatology Unit, Istituto Dermopatico dell&rsquo;Immacolata, IRCCS, Roma, ItalyAbstract: Chronic plaque psoriasis affects more tha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Saveria Pastore, Emanuela Gubinelli, Luca Leoni, Desanka Raskovic, Liudmila Korkina
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/9de126c3b1d942e69085e0b6d7c9d1c0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9de126c3b1d942e69085e0b6d7c9d1c0
record_format	dspace
spelling	oai:doaj.org-article:9de126c3b1d942e69085e0b6d7c9d1c02021-12-02T04:13:34ZBiological drugs targeting the immune response in the therapy of psoriasis1177-54751177-5491https://doaj.org/article/9de126c3b1d942e69085e0b6d7c9d1c02008-08-01T00:00:00Zhttp://www.dovepress.com/biological-drugs-targeting-the-immune-response-in-the-therapy-of-psori-a1950https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Saveria Pastore1, Emanuela Gubinelli2, Luca Leoni2, Desanka Raskovic2, Liudmila Korkina11Laboratory of Tissue Engineering and Cutaneous Physiopathology; 2Second Dermatology Unit, Istituto Dermopatico dell&rsquo;Immacolata, IRCCS, Roma, ItalyAbstract: Chronic plaque psoriasis affects more than 2% of world population, has a chronic recurrent behavior, gives a heavy burden to the patients&rsquo; quality of life, and hence remains a huge medical and social problem. The clinical results of conventional therapies of psoriasis are not satisfactory. According to the current knowledge of the molecular and cellular basis of psoriasis, it is defined as an immune-mediated chronic inflammatory and hyperproliferative skin disease. A new generation of biological drugs, targeting molecules and cells involved into perturbed pro-inflammatory immune response in the psoriatic skin and joints, has been recently designed and applied clinically. These biological agents are bioengineered proteins such as chimeric and humanized antibodies and fusion proteins. In particular, they comprise the antitumor necrosis factor-&alpha; agents etanercept, infliximab, and adalimumab, with clinical efficacy in both moderate-severe psoriasis and psoriatic arthritis, and the anti-CD11a efalizumab with selective therapeutic action exclusively in the skin. Here, we overview recent findings on the molecular pathways relevant to the inflammatory response in psoriasis and present our clinical experience with the drugs currently employed in the dermatologic manifestations, namely etanercept, infliximab, and efalizumab. The growing body of clinical data on the efficacy and safety of antipsoriasis biological drugs is reviewed as well. Particular focus is given to long-term safety concerns and feasibility of combined therapeutic protocols to ameliorate clinical results.Keywords: psoriasis, immune-mediated inflammation, etanercept, infliximab, efalizumab Saveria PastoreEmanuela GubinelliLuca LeoniDesanka RaskovicLiudmila KorkinaDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 4, Pp 687-697 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Saveria Pastore Emanuela Gubinelli Luca Leoni Desanka Raskovic Liudmila Korkina Biological drugs targeting the immune response in the therapy of psoriasis
description	Saveria Pastore1, Emanuela Gubinelli2, Luca Leoni2, Desanka Raskovic2, Liudmila Korkina11Laboratory of Tissue Engineering and Cutaneous Physiopathology; 2Second Dermatology Unit, Istituto Dermopatico dell&rsquo;Immacolata, IRCCS, Roma, ItalyAbstract: Chronic plaque psoriasis affects more than 2% of world population, has a chronic recurrent behavior, gives a heavy burden to the patients&rsquo; quality of life, and hence remains a huge medical and social problem. The clinical results of conventional therapies of psoriasis are not satisfactory. According to the current knowledge of the molecular and cellular basis of psoriasis, it is defined as an immune-mediated chronic inflammatory and hyperproliferative skin disease. A new generation of biological drugs, targeting molecules and cells involved into perturbed pro-inflammatory immune response in the psoriatic skin and joints, has been recently designed and applied clinically. These biological agents are bioengineered proteins such as chimeric and humanized antibodies and fusion proteins. In particular, they comprise the antitumor necrosis factor-&alpha; agents etanercept, infliximab, and adalimumab, with clinical efficacy in both moderate-severe psoriasis and psoriatic arthritis, and the anti-CD11a efalizumab with selective therapeutic action exclusively in the skin. Here, we overview recent findings on the molecular pathways relevant to the inflammatory response in psoriasis and present our clinical experience with the drugs currently employed in the dermatologic manifestations, namely etanercept, infliximab, and efalizumab. The growing body of clinical data on the efficacy and safety of antipsoriasis biological drugs is reviewed as well. Particular focus is given to long-term safety concerns and feasibility of combined therapeutic protocols to ameliorate clinical results.Keywords: psoriasis, immune-mediated inflammation, etanercept, infliximab, efalizumab
format	article
author	Saveria Pastore Emanuela Gubinelli Luca Leoni Desanka Raskovic Liudmila Korkina
author_facet	Saveria Pastore Emanuela Gubinelli Luca Leoni Desanka Raskovic Liudmila Korkina
author_sort	Saveria Pastore
title	Biological drugs targeting the immune response in the therapy of psoriasis
title_short	Biological drugs targeting the immune response in the therapy of psoriasis
title_full	Biological drugs targeting the immune response in the therapy of psoriasis
title_fullStr	Biological drugs targeting the immune response in the therapy of psoriasis
title_full_unstemmed	Biological drugs targeting the immune response in the therapy of psoriasis
title_sort	biological drugs targeting the immune response in the therapy of psoriasis
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/9de126c3b1d942e69085e0b6d7c9d1c0
work_keys_str_mv	AT saveriapastore biologicaldrugstargetingtheimmuneresponseinthetherapyofpsoriasis AT emanuelagubinelli biologicaldrugstargetingtheimmuneresponseinthetherapyofpsoriasis AT lucaleoni biologicaldrugstargetingtheimmuneresponseinthetherapyofpsoriasis AT desankaraskovic biologicaldrugstargetingtheimmuneresponseinthetherapyofpsoriasis AT liudmilakorkina biologicaldrugstargetingtheimmuneresponseinthetherapyofpsoriasis
_version_	1718401388911788032

Biological drugs targeting the immune response in the therapy of psoriasis

Ejemplares similares